A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Xu, JM Kato, K Hubner, Richard A Raymond, E Xu, YH Liu, SM Qazi, I Yoon, HH
Xu, JM
Kato, K
Hubner, Richard A
Raymond, E
Xu, YH
Liu, SM
Qazi, I
Yoon, HH
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Xu J-M, Kato K, Hubner RA, Raymond E, Xu Y, Liu S, et al. A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC). J Clin Oncol. 2019;37(15_suppl):TPS2656-TPS.